Business, energy, technology, markets and global industry news from Business News Today

Onswik

PharmaDeviceNews Onswik
Infographic showing Eli Lilly’s increased 2026 revenue guidance of $91 billion to $92 billion, highlighting surging Mounjaro and Zepbound sales, pipeline growth opportunities and key execution and competition risks.
Pharma & Biotech

Eli Lilly just lifted its 2026 sales outlook by $5.5bn, but can surging GLP-1 demand keep outrunning price pressure?

Eli Lilly raises 2026 revenue guidance to $91bn–$92bn as Mounjaro and Zepbound sales surge. Explore its earnings, pipeline and risks.

Read More
Eli Lilly and Company’s FDA approval for once-weekly Onswik basal insulin brings a new treatment option for adults with type 2 diabetes as competition shifts toward prescribing, patient access and real-world adoption. Representative image.
Pharma & Biotech

Eli Lilly just cut basal insulin dosing from 365 injections to 52. Can Onswik catch Novo Nordisk’s Awiqli?

Eli Lilly and Company has secured U.S. Food and Drug Administration approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, bringing a second weekly insulin into the U.S. market and shifting the competitive question from regulatory feasibility to prescribing, access and real-world adoption.

Read More